Diagnostic Tool for Non-Small Cell Lung Cancer (NSCLC) Lyophilized Serum †
Abstract
:1. Introduction
2. Materials and Methods
2.1. Collection and Preparation of Patient’s Samples
2.2. Measurements of X-ray Scattering
2.3. Calculation and Analysis of the Parameters from LAXS Data Profile
3. Results and Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ettinger, D.S.; Wood, D.E.; Aisner, D.L.; Akerley, W.; Bauman, J.; Chirieac, L.R.; D’Amico, T.A.; DeCamp, M.M.; Dilling, T.J.; Dobelbower, M.; et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2017, 15, 504–535. [Google Scholar] [CrossRef] [PubMed]
- Silvestri, G.A.; Gould, M.K.; Margolis, M.L.; Tanoue, L.T.; McCrory, D.; Toloza, E.; Detterbeck, F. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007, 132, 178S–201S. [Google Scholar] [CrossRef]
- De Wever, W.; Vankan, Y.; Stroobants, S.; Verschakelen, J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur. Respir. J. 2007, 29, 995–1002. [Google Scholar] [CrossRef]
- Zamay, T.N.; Zamay, G.S.; Kolovskaya, O.S.; Zukov, R.A.; Petrova, M.M.; Gargaun, A.; Berezovski, M.V.; Kichkailo, A.S. Current and prospective protein biomarkers of lung cancer. Cancers 2017, 9, 155. [Google Scholar] [CrossRef]
- Liu, L.; Teng, J.; Zhang, L.; Cong, P.; Yao, Y.; Sun, G.; Liu, Z.; Yu, T.; Liu, M. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer. Biomed Res. Int. 2017, 2017, 2013989. [Google Scholar] [CrossRef] [PubMed]
- Seijo, L.M.; Peled, N.; Ajona, D.; Boeri, M.; Field, J.K.; Sozzi, G.; Pio, R.; Zulueta, J.J.; Spira, A.; Massion, P.P.; et al. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. J. Thorac. Oncol. 2019, 14, 343–357. [Google Scholar] [CrossRef] [PubMed]
- Elshemey, W.M.; Desouky, O.S.; Mohammed, M.S.; Elsayed, A.A.; el-Houseini, M.E. Characterization of cirrhosis and hepatocellular carcinoma using low-angle X-ray scattering signatures of serum. Phys. Med. Biol. 2003, 48, N239–N246. [Google Scholar] [CrossRef] [PubMed]
- Desouky, O.S.; Elshemey, W.M.; Selim, N.S.; Ashour, A.H. Analysis of low-angle X-ray scattering peaks from lyophilized biological samples. Phys. Med. Biol. 2001, 46, 2099–2106. [Google Scholar] [CrossRef] [PubMed]
- Elshemey, W.M.; Desouky, O.S.; Ashour, A.H. Low-angle X-ray scattering from lyophilized blood constituents. Phys. Med. Biol. 2001, 46, 531–539. [Google Scholar] [CrossRef] [PubMed]
- Howlader, N.; Noone, A.M.; Krapcho, M.; Miller, D.; Bishop, K.; Altekruse, S.F.; Kosary, C.L.; Yu, M.; Ruhl, J.; Tatalovich, Z.; et al. SEER Cancer Statistics Review, 1975–2013, Based on November 2015 SEER Data Submission, Posted to the SEER Web Site, April 2016; National Cancer Institute: Bethesda, MD, USA, 2016. [Google Scholar]
- Li, H.; Dong, L.; Bert, C.; Chang, J.; Flampouri, S.; Jee, K.W.; Lin, L.; Moyers, M.; Mori, S.; Rottmann, J.; et al. AAPM Task Group Report 290: Respiratory motion management for particle therapy. Med. Phys. 2022, 49, e50–e81. [Google Scholar] [CrossRef] [PubMed]
- Chen, Z.; Huang, L.; Zhu, B. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer. Dis. Markers 2018, 2018, 9845123. [Google Scholar] [CrossRef] [PubMed]
Control | High Risk Group (Smokers) | NSCLC Group | |
---|---|---|---|
(n = 10) | (n = 10) | (n = 30) | |
Mean age (years) | 42 ± 3.5 | 48 ± 3.1 | 50 ± 9 |
Sex: | |||
M | 5 | 7 | 25 |
F | 5 | 3 | 5 |
UICC stage: | |||
I | ----- | ----- | 8 |
II | ----- | ----- | 17 |
III | ----- | ----- | 5 |
Normal Serum | High Risk Group | NSCLC | |||
---|---|---|---|---|---|
(n = 10) | (n = 10) | (n = 30) | F-Ratio | p-Value | |
FWHM1 (deg) | 1.96 ± 0.12 a | 1.95± 0.2 a | 2.19 ± 0.20 b | 4.906 | 0.0120 |
FWHM2 (deg) | 5.23 ± 0.14 | 5.24 ± 0.22 | 5.39 ± 0.26 | 1.898 | 0.1600 c |
Peak position 1 (deg) | 4.78± 0.15 a | 4.93 ± 0.22 b | 5.08 ± 0.16 b | 8.515 | 0.0005 |
Peak position 2 (deg) | 10.52 ± 0.16 a,b | 10.45 ± 0.22 a. | 10.62 ± 0.13 b | 3.878 | 0.0270 |
I1/I2% | 55.14 ± 2.32a | 54.20 ± 1.42 a,b | 53.10 ± 1.74 b | 3.324 | 0.0440 |
A2/A1% | 45.64 ± 5.80 a | 38.20 ± 3.82 b | 33.80 ± 3.81 b | 11.411 | 0.0001 |
Counts under peak 1 | 7.12 ± 0.22 a | 6.99 ± 0.16 a | 6..62 ± 0.19 b | 20.112 | 0.0001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mohammed, M.S.; Mohammed, A.M.S. Diagnostic Tool for Non-Small Cell Lung Cancer (NSCLC) Lyophilized Serum. Med. Sci. Forum 2023, 21, 47. https://doi.org/10.3390/ECB2023-14293
Mohammed MS, Mohammed AMS. Diagnostic Tool for Non-Small Cell Lung Cancer (NSCLC) Lyophilized Serum. Medical Sciences Forum. 2023; 21(1):47. https://doi.org/10.3390/ECB2023-14293
Chicago/Turabian StyleMohammed, Mohammed S., and Asmaa M. S. Mohammed. 2023. "Diagnostic Tool for Non-Small Cell Lung Cancer (NSCLC) Lyophilized Serum" Medical Sciences Forum 21, no. 1: 47. https://doi.org/10.3390/ECB2023-14293
APA StyleMohammed, M. S., & Mohammed, A. M. S. (2023). Diagnostic Tool for Non-Small Cell Lung Cancer (NSCLC) Lyophilized Serum. Medical Sciences Forum, 21(1), 47. https://doi.org/10.3390/ECB2023-14293